Pharmacokinetic Modeling of \((R)\)-\([^{11}\text{C}]\)verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

Lara García-Varela, David Vállez García, Takeharu Kakiuchi, Hiroyuki Ohba, Shingo Nishiyama, Tetsuro Tago, Philip H. Elsinga, Hideo Tsukada, Nicola A. Colabufo, Rudi A.J.O. Dierckx, Aren van Waarde, Jun Toyohara, Ronald Boellaard, and Gert Luurtsema*

ABSTRACT: \((R)\)-\([^{11}\text{C}]\)verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Several studies have evaluated the pharmacokinetics of \((R)\)-\([^{11}\text{C}]\)verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of \((R)\)-\([^{11}\text{C}]\)verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish \((R)\)-\([^{11}\text{C}]\)verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of \((R)\)-\([^{11}\text{C}]\)verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The \((R)\)-\([^{11}\text{C}]\)verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the \((R)\)-\([^{11}\text{C}]\)verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution \(V_T\) increased significantly up to 208% \((p < 0.001)\) and \(K_p\) up to 159% \((p < 0.001)\) compared with baseline scans. The \(K_p\) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of \(K_p\) calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates.

KEYWORDS: ABC transporters, brain imaging, efflux transporters, kinetics, P-gp tracers, rhesus monkeys

1. INTRODUCTION

\((R)\)-\([^{11}\text{C}]\)verapamil is a radiotracer used to assess the P-glycoprotein (P-gp) function at the blood–brain barrier (BBB). Verapamil is a calcium channel blocker that is used in the treatment of cardiovascular diseases such as hypertension and arrhythmias, and it is also characterized as a substrate for the efflux transporter P-gp. Therefore, \([^{11}\text{C}]\)verapamil has been used to assess the P-gp function in the human brain by positron emission tomography (PET). P-gp is a transmembrane protein that belongs to the ATP binding cassette transporter family. This transporter uses the energy provided by hydrolysis of ATP to move endogenous and exogenous compounds across the membranes. The P-gp transporter at the BBB is expressed at the luminal side of the endothelial cells, where it pumps a wide variety of substances from the brain to the blood, protecting the central nervous system (CNS) from harmful damage. P-gp dysfunctions have been related to the onset and progression of several neurodegenerative diseases and psychiatric disorders. Furthermore, numerous unrelated CNS drugs are P-gp substrates and, therefore, dysfunction in the P-gp transporter can alter the concentration of these drugs in the brain, causing toxicity issues or decreases in drug efficacy. Thus, it is of interest to evaluate the P-gp function in vivo with PET imaging.
which is a noninvasive technique and an excellent tool for quantification of biological processes.\textsuperscript{11–13} The P-gp function was evaluated for the first time in 1996 using a racemic mixture of \textsuperscript{[11C]}verapamil,\textsuperscript{2} and since then, the P-gp function has been extensively studied in humans with this tracer.\textsuperscript{7,8,14–20} \textsuperscript{[11C]}verapamil was first prepared and evaluated as a racemic mixture.\textsuperscript{2} However, the (R)- and (S)-verapamil enantiomers showed differences in the rate of metabolism, affinity to calcium channels, plasma protein binding, and clearance that complicate the pharmacokinetic quantification of the racemic tracer.\textsuperscript{1,2,4} Therefore, one of the enantiomers had to be selected for labeling. As (R)-\textsuperscript{[11C]}verapamil showed less radio-metabolites and lower affinity to calcium channels than (S)-\textsuperscript{[11C]}verapamil, it was selected as the most adequate tracer for measuring the P-gp function.\textsuperscript{24}

Since then, several studies have reported the ability of (R)-\textsuperscript{[11C]}verapamil to measure the P-gp function.\textsuperscript{15} For instance, after the administration of a P-gp inhibitor, the P-gp function is decreased and, consequently, the radiotracer is accumulated inside the brain.\textsuperscript{12–14} This tracer has a very high affinity for the P-gp transporter and, therefore, at baseline conditions, when the P-gp transporter is working adequately, the tracer uptake is very low because the P-gp transporter pumps most of the tracer out of the brain.\textsuperscript{11,25} Novel PET tracers with lower P-gp affinity have been developed to achieve higher tracer uptake in the brain at baseline conditions.\textsuperscript{10,11}

The development of new P-gp tracers that have lower affinity to the P-gp transporter (weak P-gp tracers)\textsuperscript{26,27} requires kinetic comparison with (R)-\textsuperscript{[11C]}verapamil, which is considered as the reference P-gp PET tracer because its affinity to the P-gp transporter and, therefore, at baseline conditions, when the P-gp transporter is working adequately, the tracer uptake is very low because the P-gp transporter pumps most of the tracer out of the brain.\textsuperscript{11,25} This comparison may lead to a greater understanding of the kinetic properties of weak and avid substrates. Weak P-gp tracers, such as \textsuperscript{[11C]}metoclopramide and \textsuperscript{[18F]}MC225, have been evaluated in rats and also in nonhuman primates that are more closely related to humans biologically.\textsuperscript{26,27,31} However, to perform a head-to-head comparison in nonhuman primates, a kinetic modeling evaluation of (R)-\textsuperscript{[11C]}verapamil needs to be performed in monkeys first. So far, only the kinetics of racemic \textsuperscript{[11C]}verapamil were evaluated.\textsuperscript{32–34} One study has assessed the kinetics of (R)-\textsuperscript{[11C]}verapamil in rhesus monkeys, but it did not provide a full kinetic evaluation of the tracer.\textsuperscript{35}

This study aims to assess the kinetics of (R)-\textsuperscript{[11C]}verapamil tracer at baseline and after the inhibition of the P-gp function using different scan durations (10, 20, 30, 60, and 91 min) and exploring different compartmental models. Moreover, the paper aims to determine the most suitable and reliable parameter to measure the P-gp function (and its change) at the BBB of nonhuman primates.

2. EXPERIMENTAL SECTION

2.1. Chemicals and Synthesis of the Tracer. Tariquidar (MedChemExpress, New Jersey, USA) was used as a P-gp inhibitor.\textsuperscript{25,29,36} Tariquidar solution for intravenous injection was prepared as previously described,\textsuperscript{37} with 11 mg of tariquidar methanesulfonate hydrate suspended in 3 mL of saline solution, and the injection volume was adjusted to the weight of each monkey (8 mg/kg of body weight). Radiosynthesis and quality control of (R)-\textsuperscript{[11C]}verapamil were performed as described previously.\textsuperscript{24}

2.2. Animals. Three healthy male rhesus monkeys (Macaca mulatta; Hamri Co. Ltd., Ibaraki, Japan) were included in this study that was performed at the Central Research Laboratory, Hamamatsu Photonics (Hamamatsu, Japan), in collaboration with the Tokyo Metropolitan Institute of Gerontology (Tokyo, Japan). The animals were housed individually in a controlled environment (24 ± 4 °C, 50 ± 20% of humidity under a 14 h light/10 h dark cycle) and maintained and handled in strict accordance with the recommendations of the National Institute of Health and the guidelines of the Ethics Committee of the Central Research Laboratory, Hamamatsu Photonics (approval HPK-2016-07A), and the Institutional Animal Care and Use Committee of Tokyo Metropolitan Institute of Gerontology (approval 16067).

2.3. Data Collection. 2.3.1. Experimental Design. Each nonhuman primate underwent two PET scans with (R)-\textsuperscript{[11C]}verapamil. One was performed at baseline conditions and the second one after the inhibition of the P-gp function with tariquidar. The time interval between the scans was 2 h, except for one animal where it was 2 months due to technical issues. Tariquidar was slowly injected through a catheter inserted into a saphenous vein 15 min before the PET scans at a dose of 8 mg/kg of body weight. Table 1 shows the body weight of the monkeys on the scanning day, the day of the scan, and the hour of radiotracer injection.

| Table 1. Design of the Experiments |
|-----------------------------------|
| **nonhuman primates** | **(R)-**\textsuperscript{[11C]}verapamil | **experiment** | **hour of** | **body** |
| scan | date | injection | weight (kg) |
| subject 1 | baseline | 27/12/2016 | 10:59 | 8.2 |
| subject 1 | after inhibition | 27/12/2016 | 14:45 | 8.2 |
| subject 2 | baseline | 17/02/2017 | 11:01 | 6.1 |
| subject 2 | after inhibition | 17/02/2017 | 14:03 | 6.1 |
| subject 3 | baseline | 28/02/2017 | 12:45 | 7.2 |
| subject 3 | after inhibition | 26/12/2016 | 14:01 | 6.6 |

2.3.2. PET Imaging Acquisition and Reconstruction. The same acquisition protocol was used in a previous study.\textsuperscript{37} Briefly, 1 week before the first PET scan, a brain T\textsubscript{1}-weighted magnetic resonance imaging (MRI) scan of the animal was made (Signa Excite HDTx 3.0T, GE Healthcare).\textsuperscript{38} Brain PET scans were acquired using a high-resolution animal PET scanner (SHR-38000, Hamamatsu Photonics). All nonhuman primates underwent dynamic PET scans with arterial blood sampling. Monkeys were anesthetized (2.5% sevoflurane) during the arterial cannulation and their transport, but they were awake during the scans and the head was immobilized using a fixation device. The animals were positioned in the camera in a sitting position with stereotactic coordinates aligned parallel to the orbitomeatal plane.

Prior to tracer injection, a rotating \textsuperscript{68}Ge/\textsuperscript{68}Ga rod source was used to perform the transmission scan (60 min), and its information was used for attenuation correction of the PET images. Next, animals were injected with (R)-\textsuperscript{[11C]}verapamil (more information in Table 2) at the start of the emission scan (91 min) via the saphenous vein over a period of 30 s as a single bolus.

PET images were reconstructed using the filtered back projection method with a Hanning filter of 4.5 mm in SHR-38000 Reconstruction software (Hamamatsu Photonics) and were composed of 49 frames (6 × 10, 6 × 30, 12 × 60, and 25 × 180 s).
metabolite-corrected SUV by the percentage of parent tracer. i.e. corrected for decay from the time point of tracer weight). The radioactivity measured in blood samples was measured using a gamma counter (1480 Wizard, PerkinElmer). The total amount of blood removed from the animal was less than 35 mL/day in each animal.

2.3.4. Metabolite Analysis. Parent fraction and polar radio-metabolites of (R)-[11C]verapamil in arterial blood samples were determined following the tracer injection (16, 40, and 64 s and 6, 10, 30, 45, 60, 75, and 90 min). A 0.2 mL volume of ethanol was added to the 0.1 mL of plasma fraction to deproteinize the samples. After centrifugation (13,400 rpm, 100g, for 90 s), the samples were analyzed using thin-layer chromatography plates (silica gel 60 F254, Merk) with a mobile phase of ethyl acetate/trimethylamine (9/1). The parent (Rf = 0.55) and polar-metabolized (Rf = 0.418) fractions were assessed using a phosphor imaging plate and a bioimaging analyzer (FLA-7000, Fuji Film).

The percentage of the polar radio-metabolites in plasma was calculated for each animal by fitting a single exponential equation to the values obtained from the metabolite analysis, using an iterative nonlinear least-squares approach (GraphPad Prism version 7.02, California, USA): \[ Y = Y_0 \times \exp(-K_e \times X), \]
where \( Y \) is the percentage of the parent tracer at different time points, \( Y_0 \) is the intercept, \( K_e \) is the first-order elimination constant, and \( X \) is the time.

2.4. Analysis of PET Data. 2.4.1. Time–Activity Curves of Blood Sampling: Input Function. Time–activity curves (TACs) were determined using the activity of the whole blood and plasma expressed as a standardized uptake value (SUV): \( \text{SUV} = \text{radioactive concentration}/(\text{injected dose/body weight}) \). The radioactivity measured in blood samples was corrected for decay from the time point of tracer administration. The plasma SUV–TAC corrected for polar radio-metabolites (i.e., metabolite-corrected plasma) was calculated by multiplying the SUV values of plasma samples by the percentage of parent tracer.

A single exponential equation was fitted to the radio-metabolite-corrected SUV–TAC individually using the values after the peak (from 360 to 5400 s) by an iterative nonlinear least-squares approach (GraphPad Prism version 7.02, California, USA): \[ Y = Y_0 \times \exp(-K_e \times X), \]
where \( Y \) represents the SUV values at different time points, \( Y_0 \) is the intercept, \( K_e \) is the first-order elimination constant, and \( X \) is the time. This approach allows the determination of the rate of tracer elimination (\( K_e \)) and the biological half-life (\( T_{1/2} \)): \[ T_{1/2} = \ln(2)/K_e. \]

2.4.2. PET/MRI Analysis. Images were processed using PMOD v3.8 software (PMOD Technologies, Zürich, Switzerland). All the scans were registered to a reference MRI template as previously described and the following volumes of interest (VOI) were selected for further analysis: basal ganglia, brainstem, cerebellum, cingulate cortex, orbitofrontal cortex, hippocampus, hypothalamus, insular cortex, midbrain, occipital cortex, parietal cortex, striatum, temporal cortex, thalamus, white matter, and a VOI covering the whole brain. This registration procedure and region analysis have been previously described.

The registration of the images was performed as follows. First, the MRI of the animal was registered to the reference MRI using a 3 probability maps normalization. Then, (R)-[11C]verapamil PET images were aligned to their corresponding MRI by rigid transformation using a summation of all frames. For baseline scans, the (R)-[11C]verapamil after-inhibition PET images were used as a reference because of the difficulties in the registration of MRI with the baseline PET images (the latter showing lack of anatomical information in the image and limited brain radiotracer uptake).

2.4.3. Pharmacokinetic Analysis. Several models were fitted to the VOI TACs, with the plasma-corrected for polar radio-metabolites (metabolite-corrected plasma) or non-corrected plasma TACs and the whole-blood TACs as the input function. The pharmacokinetic modeling was performed using PMOD v3.8 software.

First of all, the input functions from each animal were corrected for blood delay. The blood delay was calculated using the whole-brain TAC, and then this value was fixed for the rest of the regions. The compartmental models evaluated were the 1-tissue compartment model (1-TCM), the 2-tissue compartmental model (2-TCM), and the irreversible 2-TCM. All the models were assessed using either a fixed fractional blood volume (vB) (3, 4, 5, 6, or 7%) or using vB as a fit parameter. Data sets with different scan durations (10, 20, 30, 60, and 91 min) were analyzed in order to explore its effect on the model preference and the parameter’s estimates. The compartmental model analyses were performed twice, once with the plasma-corrected for polar radio-metabolites and then with the plasma non-corrected for radio-metabolites as the input function. No boundary restrictions were applied for the fit of the parameters during the kinetic analysis.

Akaike information criterion (AIC) was used to choose the most optimal kinetic model for each scan duration and type of scan (baseline or after inhibition). The standard errors (SE %) of the estimated parameters were also taken into consideration during model selection.

Several common kinetic parameters, that is, the influx constant \( K_i \), the volume of distribution (\( V_T \)), and the efflux constant \( k_e \), were compared between baseline and after-
inhibition scans to evaluate the effect of inhibition and to select the most appropriate parameter to measure the P-gp function.

2.5. Parametric Images. Parametric images of $K_1$, $V_T$, and $k_2$ at baseline and after inhibition were calculated in one...
monkey (subject 2) for representation purposes. The metabolite-corrected plasma TAC was used as an input function for the basis function implementation of 1-TCM using PMOD v3.8 software.

2.6. Statistical Analysis. Inferential results are reported as estimated marginal mean ± SE (mean ± SE) unless mentioned otherwise. Statistical analysis was performed using IBM SPSS Statistics version 23 (Armonk, NY, USA). Differences in kinetic parameter values and Akaike values among models, scan durations, and type of scans (baseline or after-inhibition) were assessed independently for each brain region by the generalized estimated equation (GEE) model using an independent working correlation matrix. The GEE is recommended for the analysis of longitudinal data and it is also more efficient, achieving higher power with a small sample size. The relationship between the estimated parameters calculated with different models and different data sets was explored by linear regression analysis. Results were considered statistically significant at \( p < 0.05 \), without correction for multiple comparisons. The differences between baseline and after inhibition are reported as a percentage and calculated as follows: \( 100 \times (\text{after-inhibition} - \text{baseline})/\text{baseline} \).

3. RESULTS

3.1. Tracer Production. Molar activities and radiochemical purities of \((R)-[11C]\)verapamil productions as well as the mass and radioactive dose injected in each animal are reported in Table 2.

3.2. Input Function and Metabolism of \((R)-[11C]\)verapamil. A significant increase in the area under the curve (AUC) of the whole-blood TACs was found after the administration of the P-gp inhibitor tariquidar (baseline = 2.03 ± 0.33 vs after inhibition = 2.22 ± 0.35, \( p = 0.041 \)). No statistically significant differences between baseline and after-inhibition scans were found in the uncorrected or metabolite-corrected plasma TACs (Figure 1). However, a statistically significant reduction of the % parent fraction of \((R)-[11C]\)verapamil was found after the P-gp inhibition (75.25 ± 1.37%, \( p = 0.019 \)) compared to baseline values (79.82 ± 1.37%).
According to the AIC, the best \( K_1 \) values for the whole brain using different blood and plasma TACs for blood delay, the fractional \( v_B \) was significantly change after the P-gp inhibition. After correcting the whole-brain 1-TCM and 2-TCM fits showed similar AIC values in short scan duration regions as well as in the long scan duration regions.

### 3.3. Plasma Input Models: Compartmental Models.

#### 3.3.1. Blood Volume Fraction

After correcting the whole-blood and plasma TACs for blood delay, the fractional \( v_B \) was either fixed to 3, 4, 5, 6, and 7% or used as a fit parameter. According to the AIC, the best fits were obtained when \( v_B \) was used as a fit parameter, which provided values ranging between 4 and 6%. Moreover, the SE % of the estimated parameters was also lower when \( v_B \) was fitted rather than fixed. Similar results were obtained when \( v_B \) was fixed to 5%. Supporting Information Figure S1 shows boxplots of AIC values and SE % \( K_1 \) values for the whole brain using different scan durations and models. Because fixing \( v_B \) did not improve the fits, the following analyses have been performed using \( v_B \) as the fit parameter.

#### 3.3.2. Model Selection for Different Scan Durations

The 1-TCM and 2-TCM fits showed similar AIC values in short scans, but in scans longer than 60 min, the lowest Akaike values were found using 2-TCM. Figure 2 shows the AIC for the whole brain for all tested scan durations and both scans (baseline and after inhibition) obtained with 1-TCM, 2-TCM, and irreversible 2-TCM.

For the 60 min scan, even though the lowest AIC values were found using 2-TCM, the model showed very large SE % (>100%) in the estimation of \( k_1 \), \( k_2 \), and \( V_T \). For instance, the mean SE % \( V_T \) of the whole brain at baseline using 60 min scan duration was 14,898 ± 12,158. Using 2-TCM, the SE % \( V_T \) values were in 35 cases (out of 96) higher than 100% and in 22 higher than 1000%. In the case of 91 min scan duration, 2-TCM provided lower AIC values than 1-TCM; however, some regions showed unreliable values. In 13 cases (out of 96), the SE % \( V_T \) were higher than 100% and in three cases higher than 1000%. For these reasons, 1-TCM (which showed lower SE %) was selected as the most robust model to analyze the data for all scan durations. Supporting Information Figure S2 shows representative 1-TCM and 2-TCM fits for the 30 and 91 min scans of the whole brain.

#### 3.3.3. Effect of Scan Duration

Based on our findings described above, 1-TCM was used to fit the PET data for all tested scan durations. The evaluated scan durations did not affect significantly \( K_1 \) estimations (3–13%), at least during the first 60 min of the scan. However, the estimation of \( k_2 \) decreased and the \( V_T \) increased with longer scan durations in both baseline and after-inhibition scans. In Figure 3, the effect of scan duration on the kinetic parameters of the whole brain in baseline and after-inhibition scans is shown.

### Table 3. Changes in \( V_T \), \( K_1 \), and \( k_2 \) after P-gp Inhibition in Brain Regions using 30 and 91 min Scan Durations and 1-TCM

| Scan Duration | Region          | \( K_1 \) ± SE (%) | \( V_T \) ± SE (%) | \( k_2 \) ± SE (%) |
|---------------|-----------------|--------------------|--------------------|--------------------|
| 30 min        | Basal ganglia   | 156 ± 45           | 244 ± 38           | 19 ± 4             |
|               | Brainstem       | 176 ± 46           | 241 ± 33           | 19 ± 2             |
|               | Cerebellum      | 141 ± 37           | 276 ± 42           | 35 ± 4             |
|               | Cingulate cortex| 138 ± 32           | 294 ± 41           | 40 ± 4             |
|               | Insular cortex  | 152 ± 38           | 294 ± 36           | 35 ± 5             |
|               | Midbrain        | 205 ± 57           | 305 ± 49           | 25 ± 4             |
|               | Occipital cortex| 130 ± 29           | 268 ± 35           | 37 ± 4             |
|               | Parietal cortex | 127 ± 31           | 247 ± 34           | 34 ± 4             |
|               | Striatum        | 168 ± 45           | 267 ± 40           | 27 ± 3             |
|               | Temporal cortex | 143 ± 41           | 242 ± 39           | 28 ± 4             |
|               | Thalamus        | 176 ± 41           | 285 ± 33           | 28 ± 4             |
|               | White matter    | 145 ± 36           | 268 ± 38           | 33 ± 4             |
|               | Whole brain     | 136 ± 34           | 252 ± 37           | 33 ± 4             |

*Mean values ± SE are listed, changes are shown as percentages.*
VT was most affected by the scan duration. In baseline scans, VT increased by 61% from 2.16 ± 0.24 in a 10 min scan to 3.48 ± 0.38 (p < 0.001) in a 91 min scan. Similarly, in after-inhibition scans, the VT increased by 40% from 7.88 ± 0.20 in 10 min to 10.99 ± 0.85 (p < 0.001) in a 91 min scan. The baseline VT in the 60 min scan also increased by 40% (p < 0.001) and in after-inhibition scans by 29% (p < 0.001) compared to the values in the 10 min scan. The baseline k₂ decreased by 51% in a 91 min scan and by 36% in after-inhibition scans compared to a 10 min scan.

3.3.4. Effect of P-gp Inhibition. The vB estimated by the model was not significantly different between baseline and after-inhibition scans for any of the scan durations, except for the 10 min scan duration where the estimated vB significantly increased from 0.049 ± 0.001 at baseline to 0.052 ± 0.001 after P-gp inhibition (p = 0.018).

Figure 4. Mean ± SE of K₁ for all brain regions at baseline and after-inhibition scans with different durations.

Figure 5. Parametric images of one subject using the 91 min scan data at baseline (A) and after inhibition (B), representing K₁ (mL/cm³/min, above), k₂ (1/min, center), and VT (below).
In all scan durations, the parameter most affected by P-gp inhibition was $V_T$. In 91 min scans, the whole-brain $V_T$ increased by 208% after P-gp inhibition; meanwhile, the $K_1$ increased by 159% in after-inhibition scans. The $k_2$ of the whole brain decreased by 15%. In all scan durations, $V_T$ and $K_1$ significantly increased in all the brain regions after P-gp inhibition. Meanwhile, $k_2$ significantly decreased in all scan durations except for the 91 min scan. Table 3 shows the changes in $V_T$, $K_1$, and $k_2$ after the P-gp inhibition in all the brain regions using 30 and 91 min scan durations.

The magnitude of changes is dependent on scan duration because estimated values of $V_T$ and $k_2$ are different in short and long scans. Figure 4 and Supporting Information Figures S3 and S4 show the mean values of $K_1$, $V_T$, and $k_2$ at baseline and after inhibition.

For illustrative purposes, Figure 5 shows $V_T$, $K_1$, and $k_2$ parametric images of one subject (subject 2) at baseline and after inhibition using 91 min scan and metabolite-corrected plasma as the input function.

3.3.5. Correlation $K_1-V_T$. In 60 and 91 min scans, $K_1$ and $V_T$ showed a good correlation at baseline ($R^2 = 0.74$ and $R^2 = 0.61$, $p < 0.01$) and after-inhibition scans ($R^2 = 0.70$ and $R^2 = 0.76$, $p < 0.01$, respectively). Figure 6 shows the correlation between $K_1$ and $V_T$ in 60 and 91 min scan for baseline and after-inhibition scans.

3.4. Plasma Non-corrected for Radio-Metabolite Input Models: Compartmental Models. The compartmental analyses were also performed using the plasma radioactivity non-corrected for radio-metabolites as an input function for 1-TCM in all scan durations. For most of the brain regions analyzed, the SE % of $K_1$, $k_2$, and $V_T$ was higher when using the plasma radioactivity non-corrected for radio-metabolites than with plasma-corrected for polar radio-metabolites. In 91 min scan durations, the overall SE % $V_T$ was 471% higher than the one obtained with the corrected plasma. Moreover, $V_T$ values obtained with non-corrected plasma were significantly lower than the ones obtained with plasma radioactivity corrected for polar radio-metabolites, especially in after-inhibition scans (e.g.,
in 91 min after-inhibition scans $V_T$ non-corrected plasma = 3.97 ± 0.27 vs. $V_T$ corrected plasma = 10.87 ± 0.82, $p < 0.001$). The $k_2$ values obtained with non-corrected plasma were higher than in corrected plasma in both baseline and after-inhibition scans, and the differences were more pronounced at long scan duration (>60 min). For instance, in a 91 min scan, the mean $k_2$ after inhibition obtained with non-corrected plasma was 0.13 ± 0.014 1/min, and with corrected plasma, it was 0.036 ± 0.001 1/min ($p < 0.001$).

Regarding the effect of scan duration, the estimations of $V_T$ decreased and $k_2$ increased with the scanning time when plasma non-corrected for radio-metabolites was used as the input function, whereas when plasma radioactivity was corrected for polar radio-metabolites, the estimations of $V_T$ increased and $k_2$ decreased (see Figure 7). Nevertheless, regarding P-gp inhibition, similar results were obtained compared to the analysis with metabolite-corrected plasma. The administration of tariquidar significantly increased $K_1$ and $V_T$ at all scan durations. However, the analysis did not find significant changes in $k_2$ after the P-gp inhibition. At 91 min scan duration, $K_1$ increased from 0.20 ± 0.03 ml/cm$^2$/min at baseline to 0.51 ± 0.06 ml/cm$^2$/min after inhibition ($p < 0.001$) and $V_T$ from 1.71 ± 0.22 at baseline to 3.97 ± 0.27 after P-gp inhibition ($p < 0.001$).

### 4. DISCUSSION

The aim of this study was to evaluate the kinetics of the P-gp tracer (R)-[^11C]verapamil in baseline conditions and after P-gp inhibition in nonhuman primates. Moreover, the study also evaluates the kinetics at different acquisition times (10 to 91 min) to assess the effect of the scan duration on the estimated parameters. Our results showed that 1-TCM with fractional vB as a fit parameter is the most suitable compartment model to fit the data at baseline and after-inhibition conditions for all the scan durations tested.

Model preferences seem not to be influenced by the scan duration. Although in the case of long scan durations (>60 min), the lowest AIC were seen with 2-TCM, large SE % (>100%) of the estimated parameters ($V_T$, $k_1$, and $k_2$) were found. These large SE % did not provide reliable $V_T$ values in several brain regions using 60 and 91 min scan durations. Several adjustments were applied to the model fit in an attempt to solve this problem. For instance, the use of 2-TCM while fixing the ratio $K_1/k_2$ to the whole brain gray matter value, as was suggested for the analysis of (R)-[^11C]verapamil in humans, or by imposing a lower boundary for the $k_2$ (0.001 1/min). However, none of these strategies improved the quality of the 2-TCM fit (results not reported). We have also tested a 2-input-compartmental model where we applied both a parent tracer and radio-metabolites plasma input curve at the same time in the model. This model has been already used in previous studies to account for the entrance of radio-metabolites of [^11C]verapamil in the brain. However, when using this model, we found large uncertainties in the estimated kinetic parameters ($K_1$, $k_2$, and $V_T$) (with SE % > 100%) in most of the brain regions analyzed (data not shown). The 2-input model did not provide reliable and robust results for our data and was therefore not explored in our paper. Therefore, 1-TCM was selected as the model of choice to analyze the (R)-[^11C]verapamil data in nonhuman primates for all tested scan durations and for both baseline and after-inhibition scans.

Although different kinetic analysis methods have been previously studied, a clear consensus regarding the optimal method has not yet been reached. In rats, 2-TCM showed better fits than 1-TCM for both baseline and after tariquidar administration scans. Thus, it was selected as the model of choice using either plasma-corrected for polar radio-metabolites or plasma non-corrected for radio-metabolites. In humans, several approaches have been applied to fit the (R)-[^11C]verapamil data. In healthy subjects, 1-TCM with vB as a fit parameter and using a metabolite-corrected plasma input function showed an adequate fit. 2-TCM was also applied; however, the fit did not provide robust parameters. Next, (R)-[^11C]verapamil was also assessed after the administration of tariquidar (P-gp after-inhibition scans); in this case, a 2-TCM fit was preferred, whereas the data from baseline scans (before the P-gp inhibition) was fitted with 1-TCM using a plasma input function corrected for polar radio-metabolites. Muzi et al. used 1-TCM to fit the 10 min scan duration data and 2-TCM for the 45 min scan for both baseline and after P-gp inhibition scans and corrected the plasma input function for polar and lipophilic radio-metabolites. In this study, Muzi et al. recommended the use of 10 min scan data to avoid the interference of radio-metabolites with the brain signal. Also, in humans, the use of constrained 2-TCM (i.e., fixing the ratio $K_1/k_2$ to the mean whole-brain gray matter value) was proposed, with plasma-corrected for polar radio-metabolites as the input function. The results of this analysis suggested that constrained 2-TCM leads to more reproducible results in healthy volunteers.

In our study, the administration of the P-gp inhibitor tariquidar caused a significant increase of $V_T$ and $K_1$ in all the brain regions analyzed. $V_T$ was the parameter most affected by P-gp inhibition. Tariquidar treatment caused an increase in $V_T$ of 257% ($p < 0.001$) in the 10 min scan, of 230% ($p < 0.001$) in the 60 min scan, and an increase of 208% ($p < 0.001$) in 91 min scan compared to baseline. $K_1$ was also affected by P-gp inhibition. The changes in whole-brain $K_1$ between baseline and after-inhibition scans varied from 131% in 10 min scans to 159% in 91 min scans. Moreover, we also found a significant reduction in whole-brain $k_2$ at all the scan durations except for the 91 min scan. $k_2$ was decreased by 34% in 10 min ($p < 0.001$) scans and by 15% in 91 min scans ($p = 0.072$). These results support the ability of (R)-[^11C]verapamil to detect changes in the P-gp function in nonhuman primates as has been already proven in other species.

Various studies have been done in humans under baseline and inhibition conditions. Three hours after the administration of 2 mg/kg of tariquidar by intravenous infusion over 30 min caused an increase of $V_T$ and $K_1$ by 24 ± 15 and 49 ± 36%, respectively. Another study found that the administration of tariquidar as a continuous infusion during 1 h before the PET scan and during the 60 min PET scan (total infusion time 2 h and mean tariquidar dose 5.9 ± 1.0 mg/kg) increased $V_T$ and $K_1$ values by 273 ± 78 and 259 ± 74%, respectively, relative to baseline scans. Although the inhibition of the P-gp function also caused an increase in the $K_1$ and $V_T$ values in humans, the values of the kinetic parameters, and the effect size are different from the monkeys’ values. However, because different doses of tariquidar, routes of administration, and duration of the perfusion were used in the monkeys, the human and monkey values cannot be directly compared. In rats, the P-gp inhibition also caused an increase in $K_1$ and $V_T$, but similar discrepancies were observed. Previous studies have shown that lipophilic radio-metabolites of (R)-[^11C]verapamil have similar kinetics as the parent...
tracer; thus, most of the studies use the radiotracer concentration in plasma-corrected for polar radio-metabolites as the input function for the kinetic analysis. Our kinetic analysis was performed using the radiotracer concentration in plasma-corrected for polar radio-metabolites and non-corrected for radio-metabolites as the input function. When plasma non-corrected for radio-metabolites was used, large SE % (>50%) in the parameter estimations was found. Therefore, corrections for polar radio-metabolites should be performed to avoid noisy data and low reliability of the estimated parameters. For long scan durations, \( V_T \) values calculated with plasma non-corrected for radio-metabolites as input were lower (40–60%) than with corrected plasma input, and \( K_t \) values were 100–260% higher. These lower \( V_T \) values and the decrease in \( V_T \) estimations with increasing scan durations may be caused by the higher radioactivity concentration in the input function. Therefore, if the radioactivity in blood is not corrected by the amount of radio-metabolites, the model underestimates the \( V_T \) values. When plasma-corrected for metabolites are used as the input function, the estimated \( V_T \) should not vary with the scan duration. However, because the plasma was only corrected by polar metabolites, it can be that lipophilic metabolites also accumulate in the brain, which may cause the increase in the \( V_T \) estimations with longer scan durations. Concerning the tariquidar administration, the analysis using non-corrected plasma input showed a significant increase in \( V_T \) and \( K_t \) after P-gp inhibition as was also observed when plasma-corrected for polar radio-metabolites was used. In 91 min scans, \( V_T \) increased up to 132% (\( p < 0.001 \)) in after-inhibition scans relative to baseline and \( K_t \) up to 150% (\( p < 0.001 \)). This similar effect of P-gp inhibition on \( K_t \) and \( V_T \) may allow avoiding the radio-metabolite analysis, which is considered as a time-consuming and tedious process. However, if changes in the metabolism of (R)-[11C]verapamil occur due to a disease condition or administration of treatments, the kinetic quantification can be incorrect. Therefore, the correction of plasma radioactivity for polar radio-metabolites, which have different kinetics than the parent fraction, should be performed, as was also concluded from human studies. Our baseline \( V_T \) values using either metabolite-corrected or non-corrected plasma inputs were higher than those obtained with rats. However, \( K_t \) values in rats and nonhuman primates at baseline conditions were similar. In our study, the mean whole-brain \( K_t \) value at baseline was 0.15 ± 0.02 mL/cm²/min in 91 min scans using plasma-corrected for radio-metabolites, whereas in rats, the \( K_t \) values calculated with 2-TCA and plasma-corrected for polar radio-metabolites were 0.16 ± 0.05 mL/cm²/min. Compared with human data, the \( K_t \) and \( V_T \) values obtained in our study were also higher. The baseline \( K_t \) values in humans were 0.034 ± 0.009 mL/cm²/min and increased to 0.049 ± 0.009 mL/cm²/min after P-gp inhibition. The \( V_T \) values in 40 min scans were 0.65 ± 0.13 at baseline and 0.80 ± 0.07 after inhibition, as calculated with 2-TCA. Compared with our 30 min scan duration data, baseline \( K_t \) values in nonhuman primates were 429% higher relative to humans, and the baseline \( V_T \) values were 288% higher. These different values could be caused by species differences in the expression of P-gp at the BBB. Kinetic evaluation of another strong P-gp substrate tracer, [11C]-N-desmethyl-loperamide ([11C]dLop), in nonhuman primates before and after administration of the P-gp inhibitor cyclosporine A, showed similar increases of brain uptake after P-gp inhibition as were observed in our study. The evaluation of [11C]dLop did not use compartmental models and, therefore, the brain uptake was not calculated using the \( V_T \) but using the ratio between the AUC from the brain and the AUC from the blood (AUCR = AUCbrain/AUCblood). In this study, the AUCR after the administration of the P-gp inhibitor (15 mg/kg/h i.v.) was enhanced to 10.8 ± 3.6, which is similar to our after-inhibition \( V_T \) value of the whole brain of 10.87 ± 0.82.

With regard to the tracer kinetics in plasma, it is known that (R)-[11C]verapamil suffers from extensive in vivo metabolism, both in small animals and in humans. In the present study on nonhuman primates, the percentage of parent tracer at 30 min after the injection was 57% in baseline scans and 45% in after-inhibition scans, after correction for polar radio-metabolites. Regarding the differences in parent tracer between baseline and after-inhibition scans, our analysis found a significant reduction (6%) in the percentage of parent \((R)-[11C]verapamil\) in after-inhibition scans compared to baseline. In humans, the percentage of parent tracer is around 45% at 1 h after the injection. In rats, at 30 min after tracer injection, the fraction of parent \((R)-[11C]verapamil\) in plasma was 47%, and after 1 h, it was 27%. Previous radio-metabolite studies with nonhuman primates, performed by high-performance liquid chromatography, have already reported a strong metabolism of \((R)-[11C]verapamil\) with around 80% of plasma radioactivity associated with radio-metabolites (polar and lipophilic radio-metabolites) at 30 min after the injection. Therefore, the rate of metabolism of \((R)-[11C]verapamil\) appears to be rapid and similar in different species.

Short PET scan durations are more convenient for the subjects and also to simplify the kinetic evaluation by reducing the impact of tracer metabolism. In our study, \( K_t \) values slightly decreased (3–13%) with increasing scan duration but remained relatively constant regardless of the scan duration applied. \( V_T \) was most affected by the scan duration. In the 91 min scan, \( V_T \) increased up to 61% (\( p < 0.001 \)) in baseline and 40% (\( p < 0.001 \)) in after-inhibition scans compared to the values obtained with 10 min scan duration. We also observed a decrease in \( k_t \) values (by 51% in baseline and 36% after inhibition) with increasing scan durations. This coupled increase in the \( V_T \) and decrease in the \( k_t \) estimations might be caused by the accumulation of radio-metabolites in the brain. As was found for rats and humans, radio-metabolites formed by the metabolism of \((R)-[11C]verapamil\) can cross the BBB and accumulate inside the brain. This fact may complicate the kinetic analysis of the tracer because it is not possible to differentiate the origin of the radioactive signal (radio-metabolites or parent tracer). Thus, short PET acquisition times have been proposed for the analysis of \((R)-[11C]-verapamil\). Because \( K_t \) is less affected by the scan duration than \( V_T \), we recommend the use of \( K_t \) calculated using 1-TCA and short PET scan durations to measure the P-gp function at the BBB of nonhuman primates, preferably accomplished with quantitative perfusion PET studies, allowing to differentiate between P-gp function and perfusion changes.

A potential limitation of our study is the small sample size, though the longitudinal design may reduce the subject variability and the outcomes show strong and similar inhibitory effects in all the subjects which emphasize the robustness of our results. It is also unfortunate that the study did not analyze lipophilic radio-metabolites in the blood samples. However, this analysis would require larger volumes of blood during...
blood sampling, which could be harmful to the animals and lead to errors in the pharmacokinetic analysis. An additional limitation is the position of the animals in the PET scan. In our study, the animals were sitting in the PET scan, whereas in conventional PET scanners, the subjects used to be in a supine position. This fact may change the biological function of the animals and thus alter the kinetics of the tracer. Therefore, the kinetic comparison with other PET studies must be interpreted with caution. However, this position enables the performance of the PET scans in conscious unanesthetized monkeys; thus, anesthetics will not interfere in the distribution of the tracer. Moreover, our study did not correct for partial volume effect; thus, the radioactivity of some small brain regions may be affected by spillover from regions with high tracer uptake.

This study has provided more insights into the pharmacokinetic parameters of (R)-[11C]verapamil in nonhuman primates, allowing the comparison with other species. Moreover, these results enable the head-to-head comparison of the properties of a novel P-gp PET tracer, such as [18F]MC22537 or [11C]metoclopramide, with the P-gp tracer, (R)-[11C]-verapamil, in nonhuman primates, a species larger than rodents and physiologically more similar to humans.

5. CONCLUSIONS

Our results suggest that 1-TCM is the model of choice to analyze the PET data of (R)-[11C]verapamil in nonhuman primates. The model preference is not affected by scan duration, and a similar approach should be used in baseline scans when the P-gp function is fully functional and in scans after P-gp inhibition. \( V_T \) and \( K_i \) values obtained in nonhuman primates were different from humans and rats with the same radiotracer, which highlights P-gp expression differences among species. However, the rate of (R)-[11C]verapamil metabolism seems similar in all the species examined. \( V_T \) was the parameter most affected by the challenge (P-gp inhibition). However, because the estimated \( V_T \) changes with scan duration and thus cannot be reliably determined, we recommend the use of \( K_i \) calculated with 1-TCM as a suitable parameter to measure the P-gp function at the BBB of nonhuman primates. Moreover, short scan durations are recommended to avoid quantification being affected by the presence of radio-metabolites in the brain.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c01014.

Boxplot of whole-brain AIC values and SE % \( K_i \) values using different vBs at different models, scan durations, and type of scan; representative 1-TCM and 2-TCM of one subject using 30 and 91 min scan duration at baseline and after inhibition; mean ± SE of \( k_i \) of all the brain regions at baseline and after-inhibition scans using different scan durations; and mean ± SE of \( V_T \) of all the brain regions at baseline and after-inhibition scans using different scan durations (PDF).

AUTHOR INFORMATION

Corresponding Author
Gert Luurtsema — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands; Email: g.luurtsema@umcg.nl

Authors
Lara García-Varela — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands; orcid.org/0000-0001-9803-4708
David Vállez García — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
Takeharu Kakiuchi — Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu 434-8601, Shizuoka, Japan
Hiroyuki Ohba — Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu 434-8601, Shizuoka, Japan
Shingo Nishiyama — Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu 434-8601, Shizuoka, Japan
Tetsuro Tago — Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan; orcid.org/0000-0002-9545-0922
Philip H. Elsinga — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
Hideo Tsukada — Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu 434-8601, Shizuoka, Japan
Nicola A. Colabufo — Department of Pharmacy, University of Bari Aldo Moro, Bari 70125, Italy; Biofarmdrugs, Spin-off Università degli Studi di Bari “A. Moro”, Bari 70019, Italy; orcid.org/0000-0001-5639-7746
Rudi A.J.O. Dierckx — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
Aren van Waarde — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
Jun Toyohara — Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan
Ronald Boellaard — Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.molpharmaceut.0c01014

Author Contributions
L.G.V. registered the PET images with the corresponding MRI images, did the pharmacokinetic analysis, and wrote the manuscript with help from all authors. D.Y.G. contributed to the data analysis and the preparation of the manuscript. T.K. and H.O. performed the preclinical studies. S.N. and T.T. synthesized the tracer. P.H.E. commented on the final manuscript. H.O. supervised the nonhuman primate PET study. N.A.C., R.A.J.O.D., and A.v.W. commented on the final manuscript. J.T. synthesized the tracer and contributed to the design of the preclinical experiments. R.B. contributed to the design of the pharmacokinetic analysis, helped with the

https://dx.doi.org/10.1021/acs.molpharmaceut.0c01014
Mol. Pharmaceutics 2021, 18, 416–428
interpretation of the data and the preparation of the manuscript. G.L. contributed to the design of the preclinical experiments and helped in the interpretation of the data and the preparation of the manuscript. All authors read and approved the final manuscript.

**Notes**

The authors declare no competing financial interest.

The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

### ABBREVIATIONS

[\textsuperscript{11C}]-dLop, [\textsuperscript{11C}]-N-desmethyl-loperamide; 1-TCM, 1-tissue compartment model; 2-TCM, 2-tissue compartmental model; ABC transporters, ATP binding cassette transporter; AIC, Akaike information criterion; AUC, area under the curve; BBB, blood–brain barrier; CNS, central nervous system; EMM, estimated marginal mean; GE, generalized estimated equation; Irrev 2-TCM, irreversible 2-tissue compartmental model; K_i, influx constant; K_e, efflux constant; K_re, rate of tracer elimination; PET, positron emission tomography; P-gp, P-glycoprotein; SE, standard error; SUV, standardized uptake value; T_1/2, biological half-life; TAC, time–activity curve; V_B, blood volume; VOI, volumes-of-interest; V_T, volume of distribution

### REFERENCES

(1) McTavish, D.; Sorkin, E. M. Verapamil. Drugs 1989, 38, 19–76.
(2) Elsinga, P.; van der Graaf, W. T. A.; Schuit, R. C.; van Berckel, B. N. M.; Luurtsema, G.; Molthoff, C. F. M.; Windhorst, A. D.; Smit, J. H. Use of PET Imaging to Evaluate Transporter- Mediated Drug-Drug Interactions. *J. Clin. Pharmacol.* 2016, 56, S143–S156.
(3) Wagner, C. C.; Bauer, M.; Karch, R.; Feinstein, T.; Kopp, S.; Chiba, P.; Kletter, K.; Loscher, W.; Muller, M.; Zeitlinger, M.; Langer, O. A Pilot Study to Assess the Efficacy of Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with (R)-[11C]Verapamil and {PET}. J. Cereb. Blood Flow Metab. 2009, 50, 1954–1961.
(4) Wawrzynczak, J. H.; van der Graaf, W. T. A.; Vaalburg, W.; van Berckel, B. N. M.; Luurtsema, G.; Molthoff, C. F. M.; Windhorst, A. D.; Smit, J. H. Use of PET Imaging to Evaluate Transporter- Mediated Drug-Drug Interactions. *J. Clin. Pharmacol.* 2016, 56, S143–S156.
Imaging the Impact of the P-Glycoprotein (ABC1) Function on the Brain Kinetics of Metoclopramide. J. Nucl. Med. 2016, 57, 309–314.

(28) Wanek, T.; Römermann, K.; Mairinger, S.; Stanek, J.; Sauberer, M.; Filip, T.; Trad, A.; Kuntner, C.; Pahnke, J.; Bauer, F.; Erker, T.; Löschler, W.; Müller, M.; Langer, O. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography. Mol. Pharm. 2015, 12, 3214–3225.

(29) Bauer, M.; Karch, R.; Neumann, F.; Wagner, C. C.; Klett, K.; Müller, M.; Löschler, W.; Zeitzinger, M.; Langer, O. Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood-Brain Barrier. J. Cereb. Blood Flow Metab. 2010, 30, S10–S15.

(30) Bauer, M.; Karch, R.; Zeitzinger, M.; Liu, J.; Koeppe, M. J.; Asselin, M.-C.; Sisodiya, S. M.; Hainfellner, J. A.; Wadsak, W.; Mitterhauser, M.; Müller, M.; Patarea, E.; Langer, O. In Vivo P-Glycoprotein Function before and after Epilepsy Surgery. Neurology 2014, 83, 1326–1331.

(31) Auvity, S.; Caillé, F.; Marie, S.; Winembery, C.; Bauer, M.; Langer, O.; Buvat, I.; Goutal, S.; Toumiere, N. P-Glycoprotein (ABC1) Inhibits the Influx and Increases the Eflux of 11 C-Methylspiperone across the Blood-Brain Barrier: A PET Study on Non-Human Primates. J. Nucl. Med. 2018, 59, 1609–1615.

(32) Lee, Y.-J.; Maeda, J.; Kusuhara, H.; Okauchi, T.; Inaji, M.; Nagi, Y.; Obayashi, S.; Nakao, R.; Suzuki, K.; Sugiyama, Y.; Suhara, T. In Vivo Evaluation of P-Glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil. J. Pharmacol. Exp. Ther. 2005, 316, 647–653.

(33) Schou, M.; Varnás, K.; Lundquist, S.; Nakao, R.; Amini, N.; Takeno, A.; Finnema, S. J.; Hallidin, C.; Farde, L. Large Variation in Brain Exposure of Reference CNS Drugs: A PET Study in Nonhuman Primates. Int. J. Neuropsychopharmacol. 2015, 18, py036.

(34) Ke, A. B.; Eyal, S.; Chung, F. S.; Link, J. M.; Mannikof, D. A.; Muzi, M.; Unadkat, J. D. Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, 11C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition. J. Nucl. Med. 2013, 54, 437–446.

(35) Takashima, T.; Yokoyama, C.; Mizuma, H.; Yamanaka, H.; Wada, Y.; Onoe, K.; Nagata, H.; Tazawa, S.; Doi, H.; Takahashi, K.; Morita, M.; Kanav, M.; Shibasaki, M.; Kusuhara, H.; Sugiyama, Y.; Takeno, Y.; Watanabe, Y. Developmental Changes in P-Glycoprotein Function at the Blood-Brain Barrier of Nonhuman Primates: PET Study with 11C-Verapamil and 11C-Oseltamivir. J. Nucl. Med. 2011, 52, 950–957.

(36) Mühlaier, J.; Karch, R.; Bankstahl, J. P.; Bankstahl, M.; Stanek, J.; Wanek, T.; Mairinger, S.; Müller, M.; Löschler, W.; Langer, O.; Kuntner, C. Assessment of Cerebral P-Glycoprotein Expression and Function with PET by Combined [11C]Inhibitor and [11C]Substrate Scans in Rats. Natu. Med. Biol. 2013, 40, 755–763.

(37) GarcíaVarela, D.; Kakiuchi, T.; J.; Harada, N.; T.; Takahashi, K.; Morita, M.; Kanav, M.; Shibasaki, M.; Kusuhara, H.; Sugiyama, Y.; Takeno, Y.; Watanabe, Y. Developmental Changes in P-Glycoprotein Function at the Blood-Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir. J. Nucl. Med. 2011, 52, 950–957.

(38) Huang, R.; Sumnerfield, S. G.; Salinas, C. A.; Read, K. D.; Guo, Q.; Searle, G. E.; Parker, C. A.; Jeffrey, P.; Laruelle, M. Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs. J. Cereb. Blood Flow Metab. 2012, 32, 874–883.

(40) Fan, J.; de Lannoy, I. A. M. Pharmacokinetics. Biochem. Pharmacol. 2014, 87, 93–120.